38. Zhonghua Zhong Liu Za Zhi. 2018 Mar 23;40(3):178-185. doi:10.3760/cma.j.issn.0253-3766.2018.03.004.[The therapeutic effect of HSV1-hGM-CSF combined with doxorubicin on the mousebreast cancer model].[Article in Chinese; Abstract available in Chinese from the publisher]Zhuang XF(1), Zhang SR(2), Liu BL(3), Wu JL(4), Li XQ(1), Gu HG(1), Shu Y(5).Author information: (1)Department of Oncology, the Affiliated Hospital of Jiangsu University,Zhenjiang 212000, China.(2)Department of Immunology, National Cancer Center/Cancer Hospital, ChineseAcademy of Medical Sciences and Peking Union Medical College, Beijing 100021,China.(3)Key Laboratory of Fermentation Engineer (Ministry of Education), HubeiProvincial Cooperative Innovation Center of Industrial Fermentation, Hubei KeyLaboratory of Industrial Microbiology, Hubei University of Technology, Wuhan430068, China.(4)School of Pharmacology, Hubei University of Science and Technology, Xianning437100, China.(5)Department of Central Laboratory, Affiliated Hospital of Jiangsu University,Zhenjiang 212000, China.Objective: To evaluate the oncolytic effect of herpes simplex virus type 1 which carried recombined human granulocyte-macrophage colony-stimulating factor(HSV1-hGM-CSF) on the mouse breast cancer cell line 4T1 and compare theanticancer effects of HSV1-hGM-CSF, doxorubicin alone or combination on thebreast cancer in mice. Methods: We investigated the cytotoxic effect on 4T1 cellsin vitro, the cell growth, cell apoptosis and cell cycle of 4T1 cells treatedwith oncolytic HSV1-hGM-CSF at different MOIs (0, 0.5, 1 and 2) and doxorubicinat different concentrations (0, 2, 4 and 8 μg/ml). The effects of oncolyticHSV1-hGM-CSF and doxorubicin on the tumor growth, survival time and their sideeffects on the mouse breast cancer model were observed. Results: Both oncolyticHSV1-hGM-CSF and doxorubicin significantly inhibited the proliferation of 4T1cells in vitro. Doxorubicin induced the G(2)/M phase arrest of 4T1 cells, whilethe cytotoxicity of oncolytic HSV1-hGM-CSF was no cell cycle-dependent.At day 16 after treatment with doxorubicin and HSV1-hGM-CSF, the tumor volume of 4T1 tumor bearing mice were (144.40±27.68)mm(3,) (216.80±57.18)mm(3,) (246.10±21.90)mm(3,) (327.50±44.24)mm(3,) (213.30±32.31)mm(3) and (495.80±75.87)mm(3) in the groups ofdoxorubicin combined with high dose HSV1-hGM-CSF, doxorubicin combined with lowdose HSV1-hGM-CSF, doxorubicin alone, high dose HSV1-hGM-CSF alone, low doseHSV1-hGM-CSF alone and control, respectively.Compared with the control group,both doxorubicin and HSV1-hGM-CSF treatment exhibited significant reduction ofprimary tumor volume in vivo (P<0.001). The median survival times were 48, 50,40, 42, 43 and 37 days in the six groups mentioned above, respectively. Themedian survival period of doxorubicin alone, high dose HSV1-hGM-CSF alone and lowdose HSV1-hGM-CSF alone were significantly longer than that of control (P<0.05). Conclusion: Synergistic effect of sequential treatment with doxorubicin andoncolytic HSV1-hGM-CSF is observed in 4T1 mouse breast cancer.Publisher: 目的：评价携带重组人粒细胞巨噬细胞集落刺激因子的溶瘤性1型单纯疱疹病毒(HSV1－hGM－CSF)对小鼠乳腺癌细胞系4T1的溶瘤作用，比较HSV1－hGM－CSF和阿霉素单药或联合使用治疗小鼠乳腺癌的效果。 方法： 以不同感染复数(0、0.5、1和2)的HSV1－hGM－CSF和不同浓度(0、2、4和8μg/ml)的阿霉素处理4T1细胞，观察HSV1－hGM－CSF和阿霉素在体外对4T1细胞的杀伤作用，以及对4T1细胞增殖、凋亡和细胞周期的影响。建立乳腺癌荷瘤小鼠模型，观察HSV1－hGM－CSF和阿霉素对荷瘤小鼠肿瘤生长、生存时间和毒副反应的影响。 结果：溶瘤病毒HSV1－hGM－CSF和阿霉素在体外均可以有效杀伤4T1细胞，可以明显抑制4T1细胞的增殖，阿霉素对4T1细胞细胞周期的影响主要表现为G(2)/M期阻滞，而HSV1－hGM－CSF可以均一性杀伤各细胞周期的细胞。荷瘤小鼠经阿霉素和HSV1－hGM－CSF治疗后16d，阿霉素＋高剂量HSV1－hGM－CSF组、阿霉素＋低剂量HSV1－hGM－CSF组、阿霉素组、高剂量HSV1－hGM－CSF组、低剂量HSV1－hGM－CSF组和对照组荷瘤小鼠的肿瘤体积分别为(144.40±27.68)mm(3)、(216.80±57.18)mm(3)、(246.10±21.90)mm(3)、(327.50±44.24)mm(3)、(213.30±32.31)mm(3)和(495.8±75.87)mm(3)。与对照组比较，无论是阿霉素治疗还是HSV1－hGM－CSF治疗，均可以明显缩小荷瘤小鼠的原发肿瘤体积(P<0.001)。阿霉素＋高剂量HSV1－hGM－CSF组、阿霉素＋低剂量HSV1－hGM－CSF组、阿霉素组、高剂量HSV1－hGM－CSF组、低剂量HSV1－hGM－CSF组和对照组荷瘤小鼠的中位生存时间分别为48、50、40、42、43和37d。与对照组比较，阿霉素组、高剂量HSV1－hGM－CSF组和低剂量HSV1－hGM－CSF组荷瘤小鼠的中位生存时间均明显延长(P<0.05)。 结论：溶瘤病毒HSV1－hGM－CSF联合阿霉素治疗小鼠乳腺癌具有协同抗肿瘤效应。.PMID: 29575835  [Indexed for MEDLINE]